Ostarine – MK-2866 25mg
Ostarine is presented in the ORYVION catalog as a tablet formulation containing 25mg of MK-2866 per tablet, supplied in containers of 50 tablets. Also known as enobosarm, MK-2866 is an investigational, orally active, nonsteroidal selective androgen receptor modulator (SARM).
Its mechanism of action involves binding to androgen receptors and influencing androgen-dependent signaling. Clinical research has examined its effects on lean body mass and physical function, including studies in older men and postmenopausal women. Findings from these populations do not establish its safety or effectiveness for improving athletic performance in healthy individuals.
Product Specifications:
Commercial name: Ostarine
Listed compound: MK-2866
Declared strength: 25mg per tablet
Format: Tablets
Package contents: 50 tablets
Important Note:
Clinical studies have reported reductions in HDL cholesterol, changes in hormone levels, and elevated liver enzymes with enobosarm. Serious liver injury has also been associated with SARM-containing products.
All products sold by ORYVION are intended for laboratory research purposes only and are not approved for human consumption, medical use, or veterinary applications. These compounds are not classified as dietary supplements or pharmaceuticals.
ORYVION operates strictly within the legal frameworks of the jurisdictions in which it conducts business. Sales are limited to countries and regions where the possession and use of research chemicals are permitted by law. It is the sole responsibility of the purchaser to ensure compliance with local, national, and international laws and regulations.
By purchasing, the customer affirms that they are at least 21 years of age, legally authorized to receive such materials, and fully aware of their intended use. ORYVION disclaims all liability for misuse, improper handling, or any consequences resulting from non-compliant use of these products.
ORYVION complies with relevant provisions under EU’s Pharmaceutical and Medical Device Act, as well as applicable international guidelines regarding non-pharmaceutical research compounds.